Onconetix, Inc.

Onconetix, Inc. (ONCO) reported FY 2025 revenue of $815K, down 67.7% from $2.5M in 2024, primarily due to completion of a non-recurring development services contract with Immunovia, partially offset by $0.6M license revenue from a new agreement. Gross profit was $633K (77.6% margin), improved from $1.1M (41.8% margin) due to lower cost of revenue tied to services. Net loss narrowed to -$14.0M from -$58.7M, driven by $25.4M lower impairments (goodwill $11.5M vs $32.3M; no intangibles/ENTADFI impairments vs $13.8M/$3.5M prior year) and $7.1M net other income from warrant/derivative fair value gains. Operating loss improved 68.4% to -$17.9M. Cash increased to $5.2M from prior periods via $14.5M financing (Series D/E PIPE $15.5M net), offset by $9.7M operating use. Balance sheet shows $24.9M total assets, $15.8M equity, but $3.1M working capital deficit and going concern doubt. Focus remains Proclarix commercialization amid capital needs.

Key Takeaways